Profile | GDS2987 / GI_18201885-S |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | 30.9 | 64 |
GSM215244 | HMVEC_vehicle_rep2 | 28.7 | 57 |
GSM215253 | HMVEC_vehicle_rep3 | 9.8 | 32 |
GSM215254 | HMVEC_atorvastatin_rep1 | 28.2 | 57 |
GSM215282 | HMVEC_atorvastatin_rep3 | ||
GSM215344 | HMVEC_atorvastatin_rep2 | 0.6 | 2 |
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | 35.7 | 56 |
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | ||
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | 50 | 61 |
GSM215294 | HMVEC_SLx2119_rep1 | 28.8 | 64 |
GSM215295 | HMVEC_SLx2119_rep2 | 7.5 | 16 |
GSM215296 | HMVEC_SLx2119_rep3 | 36.6 | 52 |
GSM215297 | PASMC_vehicle_rep1 | 35.1 | 47 |
GSM215298 | PASMC_vehicle_rep2 | ||
GSM215310 | PASMC_vehicle_rep3 | 0.5 | 1 |
GSM215311 | PASMC_atorvastatin_rep1 | 52.3 | 64 |
GSM215312 | PASMC_atorvastatin_rep2 | ||
GSM215313 | PASMC_atorvastatin_rep3 | 42.2 | 53 |
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | 42.3 | 56 |
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | 54.3 | 66 |
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | 31.3 | 47 |
GSM215327 | PASMC_SLx2119_rep1 | 37.5 | 54 |
GSM215328 | PASMC_SLx2119_rep2 | ||
GSM215329 | PASMC_SLx2119_rep3 | 12.6 | 24 |
GSM215330 | Fibroblasts_vehicle_rep1 | 18.1 | 39 |
GSM215331 | Fibroblasts_vehicle_rep2 | 14.6 | 39 |
GSM215332 | Fibroblasts_vehicle_rep3 | ||
GSM215333 | Fibroblasts_atorvastatin_rep1 | 19.5 | 46 |
GSM215334 | Fibroblasts_atorvastatin_rep2 | 4.6 | 13 |
GSM215335 | Fibroblasts_atorvastatin_rep3 | 21.6 | 47 |
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | 7.9 | 26 |
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | 13.4 | 40 |
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | 9.8 | 27 |
GSM215339 | Fibroblasts_SLx2119_rep1 | 6 | 18 |
GSM215340 | Fibroblasts_SLx2119_rep2 | 26.1 | 56 |
GSM215341 | Fibroblasts_SLx2119_rep3 | 37.9 | 63 |